Welcome to the Pentracor GmbH

Pentracor is a medical device company that has developed a breakthrough innovation for the treatment of acute myocardial infarction. Our first product on the German market is PentraSorb® CRP and has attracted much attention since the completion of a landmark clinical trial. Pentracor has a research and development pipeline in several therapeutic areas based on our unique expertise in immunology.

In heart attack and stroke, the C-reactive protein (CRP) leads to an increase of the primary damage. Further, the severity of rheumatic diseases is often determined by the amount of CRP.

The CRP adsorber (PentraSorb® CRP) is CE-marked. The corresponding Quality management system certificate according to EN ISO 13485 and the EC Certificate of Conformity in accordance with Directive 93/42/EEC are available.

More about the treatmentAsk questions

PentraSorb® CRP

Since November 2014 Pentracor GmbH is responsible and certified for the production and distribution of CRP adsorbers according to EN ISO 13485. The PentraSorb® CRP is an adsorber for the selective depletion of C-reactive protein (CRP).

CRP Adsorber

In the case of organ damage (e.g. heart attack or stroke), CRP marks cells capable of regeneration, which are then eliminated by the immune system. This increases the primary damage.

With the help of the PentraSorb® CRP can be removed from the blood with the aim of reducing this damage.

Read More

CRP apheresis

In CRP apheresis, CRP is selectively removed from the patient's blood plasma.

The application of PentraSorb® CRP is comparable to dialysis and can be performed in an outpatient or inpatient setting.

During the treatment, blood plasma is passed through the PentraSorb® CRP, which then selectively removes CRP from it.

Read More

Application

In principle, CRP reduction can induce therapeutic benefits in a number of acute and chronic diseases.

PentraSorb® CRP is a potential therapeutic option for diseases where elevated CRP levels are associated with a poor prognosis.

Read More

News

Second part of the second episode of our podcast has been published on YouTube

19.05.2022

Pentracast is the name of our new, informative podcast in which various employees, users and many others answer questions from our medical device consultant Henrike Weß.
This is the second part of the conversation between Henrike and Oliver

Pentracor GmbH: Blutwäscheverfahren bei akutem Herzinfarkt und Covid-19 erfolgreich

Second episode of our podcast has been published

08.04.2022

In the second episode Henrike has a chat with our colleague Oliver Wenske

Another Publication on 7 COVID patients

01.04.2022

The Journal of Clinical Medicine published an article on 7 patients with severe COVID-19 who have been treated with CRP apheresis.

German Journal "Ärzteblatt" on C-reactive protein

01.04.2022

Today the north-eastern German journal reports on C-reactive protein

Advanced training course on apheresis in acute COVID-19

06.04.2022

The event series of Brandenburg College For Nephrology starts of with the topic of CRP-Apheresis.